Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative. The dose escalation is completed, Part 2 of the study is ongoing.

Trial Details

NCT ID
NCT05752552
Phase
PHASE1
Sponsor
DeuterOncology
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • DO-2
Locations (sample)
  • Brussels, Belgium|50.85045,4.34878
  • Edegem, Belgium|51.15662,4.44504
  • Ghent, Belgium|51.05,3.71667
  • Leuven, Belgium|50.87959,4.70093
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • 18 years or older
  • histologically or cytologically confirmed locally advanced, unresectable or metastatic NSCLC, no longer eligible for approved, available standard t…
  • measurable disease in accordance with RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →